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1. Introduction
Novel coronavirus disease 2019 (COVID-19) is increasingly
recognized as a prothrombotic state with a high incidence of throm
botic complications, particularly in patients with a severe clinical
course [1,2]. However, 70–81% of COVID-19 cases are associated
with a non-severe clinical course and recover with supportive care
[3,4]. The few studies that exist estimate the venous thromboembo
lism (VTE) risk among COVID-19 patients in the general medical
wards to be between 5 and 10%, which is strikingly lower than the
30% seen in ICU patients with COVID-19 [1,5–7]. Historically, Ddimer has been utilized to exclude VTE, however, in COVID-19 pa
tients, D-dimer level has been correlated with mortality and may also
have a role in identifying patients who should be studied to rule out
VTE [8]. In patients with COVID-19 admitted to the ICU, admission Ddimer may predict risk of VTE, but it is unclear if this is true for nonsevere cases [5–7,9]. In this study, we examine the risk of and utility
of D-dimer as a predictor of VTE among COVID-19 survivors who
were not mechanically ventilated and were successfully discharged
from the hospital.
2. Methods
This is a retrospective cohort analysis of all adult patients discharged
from a large, urban, tertiary teaching health system between March 11,
2020 and May 2, 2020. This study was approved by the Institutional
Review Board (IRB) at Albert Einstein College of Medicine.
The study included adult patients hospitalized with COVID-19 who
were discharged from the hospitalization. COVID-19 status was
confirmed by Real-Time polymerase chain reaction. Hospital admission
date was the cohort entry date. Patients were excluded if they were
mechanically ventilated or expired regardless of VTE status. The final
cohort included patients who underwent imaging during hospitalization

or within 14 days of discharge that could identify a new pulmonary
embolism (PE) or deep vein thrombosis (DVT).
Clinical and demographic characteristics of identified patients were
extracted from our electronic medical record. The first available labo
ratory value within 48 h of admission was reported. Thromboprophy
laxis and full dose anticoagulation prior to diagnosis as well as imaging
data were extracted via manual chart review.
The primary outcome was a VTE event which was a composite of
DVT, PE, or both as identified by lower or upper extremity duplex
studies for DVT or chest computerized tomography (CT) with contrast
for PE. Studies completed up to 14 days after discharge date were
included. Imaging was performed at the providers’ discretion.
Patients with and without confirmed VTE were compared using Chisquared for categorical variables and unpaired Student’s t-test for
continuous variables or nonparametric alternatives. Two measures of
VTE prevalence were calculated. The Test Positivity Rate represents the
proportion of tested patients in whom VTE was found. To provide a floor
estimate of the prevalence of VTE in the population, the Estimated
Population Prevalence (positive tests divided by number of eligible nonsevere patients) was calculated.
D-dimer value on admission was stratified into four categories
using integers for simplicity in clinical practice. The reference Ddimer category was <1 μg/mL, mild elevation was ≥1–2 μg/mL,
moderate elevation was ≥2–5 μg/mL, and D-dimer ≥5 μg/mL was a
severe elevation.
Logistic regression models were used to examine the association
between D-dimer level and VTE events. Adjusted models included var
iables determined a priori to be potential confounders (gender, age,
body mass index (BMI), CRP, ferritin, and LDH), and a separate model
included variables significant on bivariate analysis. Goodness of fit was
checked by Hosmer-Lemeshow test. All statistical analysis was per
formed using Stata version 16.1 (StataCorp LLC, College Station, Texas).
All p < 0.05 in a two-tailed test were statistically significant.

Abbreviations: COVID-19, coronavirus disease 2019; VTE, venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism.
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3. Results

Table 1
Baseline characteristics of patients with confirmed VTE and without confirmed
VTE.

A total of 3855 eligible adult patients with COVID-19 were identified
and 1225 were excluded for mortality or mechanical ventilation during
admission. Of the remaining 2630 patients, 306 underwent diagnostic
imaging for VTE. Sixty-seven of these 306 patients had confirmed VTE
leading to a Test Positivity Rate of 21.9% (67/306). The Estimated
Population Prevalence was 2.5% (67/2630).
Of the 306 imaged patients, 92 underwent VTE imaging within 24 h
of presentation and thus did not receive thromboprophylaxis. Of the
remaining 214 patients, 21 (9.8%) received no thromboprophylaxis or
anticoagulation, 116 (54.2%) received thromboprophylaxis and 77
(36.0%) received full dose anticoagulation.
Patients with and without confirmed VTE were of similar age (60.6
versus 61.7 years, p = 0.60), BMI (31.1 versus 30.3, p = 0.44) and race/
ethnicity (p = 0.964) (Table 1). Patients with confirmed VTE were more
likely to be male (67.2% versus 51.9%, p = 0.03). Patients with VTE also
had higher white blood cell count (9.6 versus 7.5 k/μL, p = 0.008), LDH
(464 versus 370 mg/dL, p = 0.005), neutrophil/lymphocyte ratio (0.8
versus 0.4, p = 0.009) and lower fibrinogen (594 versus 645 mg/dL, p =
0.07) than those without confirmed VTE.
Admission D-dimer levels were higher in patients with confirmed
VTE (5.2 versus 1.7 μg/mL, p <0.001) among the 250 patients with
admission D-dimer level. Among patients with a D-dimer who did not
undergo any VTE imaging (n = 1586), median D-dimer level was 1.23
μg/mL (IQR 0.71 to 2.45 μg/mL) (not shown in Table 1).
There was an incremental and dose-dependent effect of admission Ddimer in predicting confirmed VTE (Table 2). Among imaged patients
with reference D-dimer (<1 μg/mL) levels, the Test Positivity Rate was
7.6% and Estimated Population Prevalence was 0.7%. Test Positivity
Rate and Estimated Population Prevalence were incrementally higher in
the mildly (≥1–2 μg/mL) and moderately (≥2–5 μg/mL) elevated Ddimer levels compared to those with reference D-dimer level. Likewise,
the odds of confirmed VTE were increased among mildly and moder
ately elevated D-dimer categories but non-significant compared to the
reference D-dimer. Finally, for the severely elevated D-dimer category
(≥5 μg/mL), the Test Positivity rate was 46.7% while Estimated Popu
lation Prevalence was 11.6%. The odds of confirmed VTE in the severely
elevated D-dimer category demonstrated a tenfold increase in odds (OR
10.7, 95% CI: 3.7–30.3, p<0.001) as compared to the lowest category.
Models with variables chosen a priori for adjustment (age, gender, BMI,
CRP, ferritin, and LDH) and variables significant in bivariate analysis for
adjustment (gender, WBC, neutrophil count, lymphocyte count, LDH)
yielded similar odds ratios (Supplementary Table 1).

Age, years (SD)
BMI, kg/m2 (SD)a
Length of stay, days
(SD)
Male sex, n (%)
Race/ethnicity, n
(%)
Hispanic
Black, not
Hispanic
White, not
Hispanic
Other/not
specified
Comorbidity, n (%)
Hypertension
Diabetes mellitus
Malignancy
Laboratory tests
reported as
median [IQR]
WBC (4.8–10.8
k/μL)
Neutrophil count
(1.8–7.7 k/μL)
Neutrophil/
lymphocyte ratio
Hb (14.0–17.4 g/
dL)
Platelet
(150–400 k/μL)
Sodium
(135–145 mEq/
L)a
Creatinine
(<1.50 mg/dL)
Carbon dioxide
(20–30 mEq/L)a
D-dimer
(0.00–0.50 μg/
mL)a
Procalcitonin
(<0.1 ng/mL)a
CRP (<0.8 mg/
dL)a
IL-6 (<5.00 pg/
mL)a
Ferritin (25–270
ng/mL)a
LDH (<240 mg/
dL)a
Fibrinogen
(187–502 mg/
dL)a

4. Discussion
In this large retrospective cohort study of non-severe COVID-19 pa
tients who were not mechanically ventilated and survived to discharge,
admission D-dimer level conferred an incremental, dose-dependent and
predictable association with the odds of having a confirmed VTE during
admission or within fourteen days following discharge. Our work sug
gests that not only do non-severe hospitalized COVID-19 patients have
an elevated risk of VTE, but admission D-dimer level may help identify
those at highest risk, creating opportunities for risk mitigation or po
tential treatment options to ameliorate the complications of VTE. Ddimer elevation has been previously associated with VTE in patients
with COVID-19, however, these studies utilized small populations and
severely ill patients which limits generalizability to most COVID-19
patients [5–7,9]. Admission D-dimer level conferred a predictable,
dose-dependent, and incremental odds of confirmed VTE between 2.3fold and 10.7-fold for categories of D-dimer above 1 μg/mL among
non-severe COVID-19 patients. While D-dimer has been historically used
for its high negative predictive value for VTE, given the degree of
elevation in COVID-19 patients, it may have utility in stratifying VTE
risk.

Total scans
(N = 306)

Without
confirmed VTE
(N = 239)

Confirmed
VTE (N = 67)

61.5 (15.7)
30.4 (7.6)
9.9 (6.7)

61.7 (15.8)
30.3 (7.6)
9.4 (6.2)

60.6 (15.7)
31.1 (7.3)
11.6 (7.9)

0.60
0.44
0.06

169 (55.2)

124 (51.9)

45 (67.2)

0.03
0.96

114 (37.3)
126 (41.2)

89 (37.2)
97 (40.6)

25 (37.3)
29 (43.3)

20 (6.5)

16 (6.7)

4 (6.0)

46 (15.0%)

37 (15.5)

9 (13.4)

190 (62.1)
112 (36.6)
67 (21.9)

148 (61.9)
91 (38.1)
60 (22.5)

42 (62.7)
21 (31.3)
7 (18.0)

0.91
0.31
0.52

8.0
[5.8–10.8]
5.8 [4.2–8.8]

7.5 [5.7–10.2]

0.01

0.4 [0.2–1.0]

0.4 [0.2–0.9]

9.6
[6.2–12.3]
7.9
[4.6–10.1]
0.8 [0.3–1.3]

12.8
[11.1–14.3]
235
[172–325]
136
[133–140]

12.6
[11.0–14.1]
219
[172–302]
136
[133–140]

13.2
[11.5–14.5]
276
[189–365]
136
[133–141]

0.15

1.0 [0.8–1.6]

1.0 [0.8–1.5]

1.1 [0.8–1.9]

0.31

23 [20–25]

23 [20–25]

23 [20–25]

0.55

1.9 [0.9–4.9]

1.7 [0.9–3.5]

5.2
[1.9–20.0]

<0.001

0.2 [0.1–0.6]

0.2 [0.1–0.7]

0.2 [0.1–0.5]

0.33

9.9
[3.7–20.6]
34.3
[10.6–65.5]
749
[327–1617]
392
[283–524]
634
[506–791]

9.5 [3.4–20.4]

11.4
[4.7–21.2]
45.2
[11.9–65.5]
908
[399–1957]
464
[328–638]
594
[406–791]

0.27

5.7 [4.0–8.3]

28.0
[10.4–66.3]
728
[320–1537]
370
[266–513]
645
[524–788]

pValue

0.008
0.009

0.06
0.93

0.38
0.18
0.005
0.07

For laboratory results, normal ranges are reported in parenthesis.
Laboratory reported values are the initial result within 48 h of admission.
Abbreviations: SD – standard deviation, VTE - venous thromboembolism, BMI body mass index, WBC - white blood cell, Hb - hemoglobin, CRP - C-reactive
protein, IL-6 - interleukin-6, LDH - lactate dehydrogenase.
a
Observations available for analysis: BMI 297, sodium and carbon dioxide
305, D-dimer 250, procalcitonin 193, CRP 265, IL-6 165, ferritin 231, LDH 276,
fibrinogen 197.

The 2.5% Estimated Population Prevalence in the non-severe COVID19 population is on par with the risk of developing a symptomatic VTE
following a high-risk surgical procedure (neurosurgery, major vascular
surgery, total hip replacement, or radical cystectomy) [10]. Admission
D-dimer identified populations with lower and higher prevalence of
VTE, from 0.7% in the reference D-dimer category to 11.6% in the
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Table 2
Test Positivity Rate, Estimated Population Prevalence, and odds of developing
imaging confirmed VTE during admission or within fourteen days of discharge
based on D-dimer category.
Ddimer
rangea

Number of
patients in
range

Test
positivity
Rate
n (%)

Estimated
Population
Prevalence
n (%)b

Odds ratio
(95% CI)c

p-Value

<1 μg/
mL
≥1 to
<2
μg/
mL
≥2 to
<5
μg/
mL
≥5 μg/
mL

66

5 (7.6%)

5 (0.7%)

Reference

Reference

62

10
(16.1%)

10 (2.0%)

2.3
(0.8–7.3)

0.1

62

12
(19.4%)

12 (3.1%)

2.9
(1.0–8.9)

0.06

60

28
(46.7%)

28 (11.6%)

10.7
(3.7–30.3)

p < 0.001
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a
Normal D-dimer range: 0.00–0.5 μg/mL. The 1–2 μg/mL range excludes 2
μg/mL. The 2–5 μg/mL range excludes 5 μg/mL. There were 56 patients with

imaging but without admission D-dimer result who were not included in the
analysis.
b
Percentage of imaging that confirmed presence of VTE out of eligible nonsevere patients.
c
Unadjusted odds ratio shown here. Adjusted models did not yield meaningful
differences in odds ratios (Supplementary Table 1).

severely elevated D-dimer category (D-dimer ≥5 μg/mL). While these
categories were not intended to guide clinical decisions, they may begin
to offer potential for clinical care. For example, it might seem reasonable
to initiate diagnostic testing or pursue more aggressive thrombopro
phylaxis for those with an 11.6% risk of VTE.
This retrospective analysis has some limitations. First, this study was
performed in one hospital system that serves a socioeconomically
disadvantaged population and may not be generalizable. VTE risk is
known to be higher in the African-American population which composes
a large proportion of our patients [11]. Secondly, we could not evaluate
our primary outcome in any patient without appropriate imaging, which
was complicated during the pandemic when in-hospital movement of
highly contagious patients was limited; this likely led to an underdiag
nosis of VTE and underestimate of VTE risk. Thirdly, a D-dimer result
was not available for all imaged patients. Given the standard practice to
initiate therapeutic anticoagulation if pre-test probability for VTE was
high without checking D-dimer, true population VTE prevalence is likely
higher than our estimation.
In sum, these findings suggest that physicians should have a high
index of suspicion for VTE in patients admitted with non-severe COVID19. In addition, admission D-dimer levels may help stratify VTE risk
among admitted non-severe COVID-19 patients, thereby aiding with
diagnostic and potential treatment decisions to ameliorate the compli
cations of VTE.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.thromres.2020.12.023.
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